Pomdoctor Gets Nasdaq Deficiency Letters
Digital healthcare firm POMDOCTOR LIMITED has until April 26, 2027 to regain compliance with two Nasdaq market value requirements.
Updated on Nov. 2, 2026 in Public Companies
Nasdaq's Listing Qualifications Department sent POMDOCTOR LIMITED two deficiency letters on October 28, 2026, after its market value of listed securities and market value of publicly held shares fell below continued listing thresholds. The company has 180 calendar days to regain compliance with both requirements.
Why it matters
Failure to regain compliance within the compliance period would result in written notification that the company's securities are subject to delisting from Nasdaq. For investors in the stock, listed as POM, the letters signal that the company's market capitalization has dropped below thresholds that the exchange requires for continued listing.
Nasdaq measured the company's market value of listed securities and market value of publicly held shares over 30 consecutive business days, from September 16 through October 27, 2026, against thresholds of $50 million and $15 million. Regaining compliance requires each measure to close at or above its threshold for at least 10 consecutive business days within the 180-day window ending April 26, 2027.
The players
POMDOCTOR LIMITED
A digital healthcare company headquartered in Guangzhou, China, whose shares trade on Nasdaq under the ticker POM.
Nasdaq
A major U.S. stock exchange that sets continued listing standards, including minimum market value requirements, for companies whose shares trade on its platform.
The details
Nasdaq's Listing Qualifications Department issued two separate letters to POMDOCTOR LIMITED on October 28, 2026, one for each requirement. The company is a digital healthcare company listed on Nasdaq under the ticker POM, and its letters are based on a measurement period that ended October 27, 2026.
Timeline
September 16, 2026 through October 27, 2026: 30-business-day measurement period for both deficiencies.
October 28, 2026: Nasdaq sends the two deficiency letters.
April 26, 2027: End of the 180-day compliance period for both requirements.
Market Landscape
The letters are issued under Nasdaq Listing Rule 5450(b)(3)(A), which sets the market value thresholds that determine whether a listed company qualifies for continued trading on the exchange. Companies that fall below these thresholds receive a fixed 180-calendar-day cure period, after which non-compliance leads to a delisting process.
Shareholders in POM face the possibility of delisting if the company cannot restore its market value above Nasdaq's thresholds within the 180-day window. Trading in a delisted stock typically moves to less regulated markets, which can reduce liquidity for holders.
The takeaway
A deficiency letter is a warning with a defined cure period, not an immediate delisting, and the company's ability to lift its market value within six months will determine the outcome. Investors should track the company's market capitalization and any compliance filings ahead of the April 2027 deadline.
What happens next
The company must regain compliance with both the MVLS and MVPHS requirements by April 26, 2027, or face a written delisting notification from Nasdaq.
Further reading
Explore more stock exchange compliance coverage in the Public Companies section.
